RS66515B1 - Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću - Google Patents

Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću

Info

Publication number
RS66515B1
RS66515B1 RS20250161A RSP20250161A RS66515B1 RS 66515 B1 RS66515 B1 RS 66515B1 RS 20250161 A RS20250161 A RS 20250161A RS P20250161 A RSP20250161 A RS P20250161A RS 66515 B1 RS66515 B1 RS 66515B1
Authority
RS
Serbia
Prior art keywords
migalastat
salt
patients
patient
gal
Prior art date
Application number
RS20250161A
Other languages
English (en)
Serbian (sr)
Inventor
Jeff Castelli
Jay Barth
Nina Skuban
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63528948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS66515(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of RS66515B1 publication Critical patent/RS66515B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20250161A 2017-08-28 2018-08-28 Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću RS66515B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762550984P 2017-08-28 2017-08-28
EP22194251.9A EP4176877B1 (en) 2017-08-28 2018-08-28 Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease

Publications (1)

Publication Number Publication Date
RS66515B1 true RS66515B1 (sr) 2025-03-31

Family

ID=63528948

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20250161A RS66515B1 (sr) 2017-08-28 2018-08-28 Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću
RS20221061A RS63742B1 (sr) 2017-08-28 2018-08-28 Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20221061A RS63742B1 (sr) 2017-08-28 2018-08-28 Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću

Country Status (26)

Country Link
US (1) US20200222377A1 (enExample)
EP (3) EP3675853B1 (enExample)
JP (3) JP7755929B2 (enExample)
KR (2) KR102790184B1 (enExample)
CN (1) CN111770753A (enExample)
AR (1) AR112482A1 (enExample)
AU (2) AU2018326364B2 (enExample)
CA (1) CA3074450C (enExample)
CL (1) CL2020000491A1 (enExample)
DK (2) DK4176877T3 (enExample)
EA (1) EA202090564A1 (enExample)
ES (2) ES2931054T3 (enExample)
FI (1) FI4176877T3 (enExample)
HR (2) HRP20250064T1 (enExample)
HU (2) HUE070433T2 (enExample)
IL (3) IL272893B2 (enExample)
LT (2) LT4176877T (enExample)
MX (2) MX2020002229A (enExample)
PL (2) PL4176877T3 (enExample)
PT (2) PT4176877T (enExample)
RS (2) RS66515B1 (enExample)
SG (1) SG11202001707PA (enExample)
SI (1) SI4176877T1 (enExample)
SM (2) SMT202500073T1 (enExample)
TW (1) TWI845479B (enExample)
WO (1) WO2019046244A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en) 2017-05-30 2020-01-23 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
EP4717319A3 (en) 2018-02-06 2026-06-10 Amicus Therapeutics, Inc. Methods of treating fabry disease in pregnant patients
LT3840753T (lt) 2018-08-20 2024-11-11 Amicus Therapeutics, Inc. Migalastatas skirtas naudoti fabry ligos gydymo būdui, pacientams turintiems gla geno mutaciją
KR20220044560A (ko) * 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
TR2024011149A1 (tr) 2024-08-23 2026-03-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇galastat i̇çeren kapsül formülasyonlari
CN119120696A (zh) * 2024-11-12 2024-12-13 北京贝瑞和康生物技术有限公司 检测法布雷病gla基因突变的引物组、试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc METHOD FOR THE TREATMENT OF MORBUS FABRY WITH PHARMACOLOGICAL CHAPTERONES
US9999618B2 (en) * 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2019046244A1 (en) 2017-08-28 2019-03-07 Amicus Therapeutics, Inc. METHODS FOR ENHANCING AND / OR STABILIZING CARDIAC FUNCTION IN PATIENTS WITH FABRY DISEASE
US10811814B2 (en) 2017-08-28 2020-10-20 John Mezzalingua Associates, LLC Weather protecting (WP) housing for coaxial cable connectors

Also Published As

Publication number Publication date
IL272893B2 (en) 2024-07-01
CN111770753A (zh) 2020-10-13
HUE060287T2 (hu) 2023-02-28
SG11202001707PA (en) 2020-03-30
HUE070433T2 (hu) 2025-06-28
FI4176877T3 (fi) 2025-03-06
PT3675853T (pt) 2022-11-28
PL4176877T3 (pl) 2025-04-07
EP4176877B1 (en) 2024-12-04
CL2020000491A1 (es) 2020-09-11
EP4176877A1 (en) 2023-05-10
CA3074450C (en) 2024-10-01
DK3675853T3 (da) 2022-11-28
IL310648A (en) 2024-04-01
WO2019046244A1 (en) 2019-03-07
EP3675853B1 (en) 2022-09-07
RS63742B1 (sr) 2022-12-30
SMT202200459T1 (it) 2023-01-13
JP7755929B2 (ja) 2025-10-17
BR112020003974A2 (pt) 2020-09-01
IL272893B1 (en) 2024-03-01
EP4588476A1 (en) 2025-07-23
IL324182A (en) 2025-12-01
EA202090564A1 (ru) 2020-06-15
KR20200044908A (ko) 2020-04-29
TW201919619A (zh) 2019-06-01
DK4176877T3 (da) 2025-02-24
IL272893A (en) 2020-04-30
SI4176877T1 (sl) 2025-03-31
CA3074450A1 (en) 2019-03-07
TWI845479B (zh) 2024-06-21
KR20250049561A (ko) 2025-04-11
KR102790184B1 (ko) 2025-04-01
HRP20221366T1 (hr) 2023-01-06
PL3675853T3 (pl) 2022-12-27
EP3675853A1 (en) 2020-07-08
HRP20250064T1 (hr) 2025-03-14
PT4176877T (pt) 2025-02-24
JP2020531550A (ja) 2020-11-05
MX2023005628A (es) 2023-05-24
SMT202500073T1 (it) 2025-03-12
US20200222377A1 (en) 2020-07-16
ES3013820T3 (en) 2025-04-15
LT4176877T (lt) 2025-02-10
MX2020002229A (es) 2020-07-20
AU2024266945A1 (en) 2024-12-19
JP2025138638A (ja) 2025-09-25
AU2018326364A1 (en) 2020-04-09
LT3675853T (lt) 2022-12-12
JP2023051998A (ja) 2023-04-11
AU2018326364B2 (en) 2024-08-29
AR112482A1 (es) 2019-10-30
ES2931054T3 (es) 2022-12-23

Similar Documents

Publication Publication Date Title
EP4324521B1 (en) Migalastat for use in the treatment of fabry disease in ert-naive and ert-experienced patients
TWI845479B (zh) 增強及/或穩定Fabry氏症患者之心臟功能之方法
US20240277687A1 (en) Methods of treating fabry disease in patients having a mutation in the gla gene
EP3749308B1 (en) Treatment of patients with classic fabry disease with migalastat
RS67913B1 (sr) Postupci lečenja fabrijeve bolesti
WO2019017938A1 (en) TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
JP7749572B2 (ja) Gla遺伝子の突然変異を有する患者におけるファブリー病を治療する方法
JP7680356B2 (ja) ファブリー病患者の脳血管事象のリスク低減におけるミガロスタットの使用
CA3090499C (en) Use of migalastat for the treatment of patients with classic fabry disease
HK40128496A (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
BR112020003974B1 (pt) Métodos para intensificar e/ou estabilizar função cardíaca em pacientes com doença de fabry
EA045263B1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри